Northland Securities Maintains Their Hold Rating on Dexcom (DXCM)

Northland Securities analyst Suraj Kalia maintained a Hold rating on Dexcom (DXCMResearch Report) today and set a price target of $125. The company’s shares opened today at $141.90, close to its 52-week high of $152.14.

Kalia wrote:

“We are introducing FY20 numbers with revenues in the $1.45B range. Dexcom continues to fire on all cylinders, although the key question remains….how will the competitive environment stack up moving forward? Maintain our rating / PT.”

According to TipRanks.com, Kalia is a 5-star analyst with an average return of 9.4% and a 55.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Dexcom is a Moderate Buy with an average price target of $148.91, representing a 4.9% upside. In a report issued on January 2, Morgan Stanley also maintained a Hold rating on the stock with a $135 price target.

.

See today’s analyst top recommended stocks >>

Based on Dexcom’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $46.6 million. In comparison, last year the company earned revenue of $221 million and had a GAAP net loss of $9.4 million.

Based on the recent corporate insider activity of 107 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DXCM in relation to earlier this year. Earlier this month, Jay Skyler, a Director at DXCM bought 25,806 shares for a total of $118,191.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.

Leave a Reply

Your email address will not be published. Required fields are marked *